ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

Browse : By Sponsor : Industry : Vion Pharmaceuticals


Include trials that are no longer recruiting patients.

15 studies were found.
1.No longer recruiting3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors
Condition: unspecified adult solid tumor, protocol specific
2.No longer recruiting3-AP and Cytarabine in Treating Patients With Hematologic Cancer
Conditions: acute leukemia; atypical chronic myeloid leukemia; chronic leukemia; myelodysplastic and myeloproliferative disease
3.Recruiting3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
Conditions: recurrent non-small cell lung cancer; stage IV non-small cell lung cancer
4.Suspended3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
Conditions: stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer; recurrent pancreatic cancer
5.No longer recruiting3-AP in Treating Patients With Advanced Cancer
Condition: unspecified adult solid tumor, protocol specific
6.No longer recruiting3-AP in Treating Patients With Advanced Prostate Cancer
Conditions: recurrent prostate cancer; stage IV prostate cancer
7.No longer recruiting3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
Condition: unspecified adult solid tumor, protocol specific
8.CompletedCombination Chemotherapy in Treating Patients With Advanced Cancer
Condition: unspecified adult solid tumor, protocol specific
9.No longer recruitingVNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Prior Therapy
Condition: unspecified adult solid tumor, protocol specific
10.No longer recruitingVNP20009 in Treating Patients With Advanced Solid Tumors
Condition: unspecified adult solid tumor, protocol specific
11.RecruitingVNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
Conditions: adult acute lymphoblastic leukemia; adult acute myeloid leukemia; childhood acute myeloid leukemia and other myeloid malignancies; ...
12.RecruitingVNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Conditions: adult acute myeloid leukemia; atypical chronic myeloid leukemia; Chronic Myelomonocytic Leukemia; myelodysplastic and myeloproliferative disease; ...
13.No longer recruitingVNP40101M in Treating Patients With Advanced or Metastatic Cancer
Conditions: adult solid tumor; Leukemia; Lymphoma; small intestine cancer
14.CompletedVNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
Conditions: adult solid tumor; Leukemia; Lymphoma; small intestine cancer
15.No longer recruitingVNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
Conditions: acute leukemia; atypical chronic myeloid leukemia; chronic leukemia; Hairy Cell Leukemia; myelodysplastic and myeloproliferative disease; ...

line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act